Paroxysmal nocturnal haemoglobinuria (PNH) is a rare condition with an estimated prevalence of approximately 16 per million. PNH originates from an acquired mutation in the PIGA (phosphatidylinositol glycan anchor biosynthesis, class A) gene in a self-renewing haematopoietic stem cell, followed by clonal expansion.
The therapy for PNH patients depends on the severity of symptoms and the degree of haemolysis. For patients with classic PNH, allogeneic haematopoietic stem cell transplantation and complement inhibition with eculizumab (Soliris®) are the only approved therapeutic options.
Since 2008, patients have been included in a global PNH registry.
The primary aim of this registry is to collect and evaluate pharmacovigilance and efficacy data of patients treated with eculizumab.
In this paper, the diagnosis and management of PNH patients are reviewed, with a focus on identifying high-risk groups of patients.
Identifying these patients without delay is crucial and recommended by international guidelines. 5, 6 Moreover, the implementation and prognostic value of the defined high-risk groups is commented on. Secondly, the management of PNH patients is discussed from
Belgian experience and recommendations are provided in order to advise on treatment possibilities in PNH under the current Belgian reimbursement criteria. Recommendations Taxonomy (SORT) was used. 7 
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| Historical development of PNH diagnosis
Historically, the diagnosis of PNH was achieved by assays designed to sensitise the complement lysis activity on RBCs. The acidified serum lysis test (Ham test) was commonly used and is now replaced in most countries by a flow cytometric (FCM) analysis of glycosyl phosphatidylinositol-anchored proteins (GPI-AP). 8 Flow cytometry
should be used to diagnose PNH (recommendation level A).
Initially, FCM assays mainly were based on the detection of CD59 (membrane inhibitor of reactive lysis) and CD55 (decay accelerating factor) on RBCs. With this technique, type I (normal), type II (partial deficiency of GPI-AP) and type III (complete deficiency of GPI-AP) RBCs could be quantified, that provided an estimation of the haemolysis severity. However, it was recognised that both haemolysis and transfusion would underestimate the clone size derived from RBC analyses, and therefore, analysis of CD55
and CD59 was also applied to granulocytes, which have a normal lifespan PNH. To exclude rare inherited deficiencies of a single GPI-AP, the diagnosis of PNH requires decreased expression of both CD55 and CD59. 2, 5, 6 Because of improved flow cytometry technologies, in both reagents and equipment, new detailed guidelines on PNH assays were issued.
| Current recommendations for PNH testing
Deficiency of GPI-APs in PNH affects all white blood cell (WBC) lineages, although this is more variable in lymphocytes. An analysis of 5000-10 000 target cells is recommended to achieve a PNH clone detection with a sensitivity of 1%. 5, 6 The clone size is best quantified by the analysis of granulocytes, since they represent the predominant cell class (recommendation level A). Clone sizes estimated from a monocyte analysis generally parallel those obtained from a granulocyte analysis. However, it may be more laborious in some patients to acquire 5000-10 000 monocyte events. Nonetheless, assays targeting both granulocytes and monocytes should be preferred for obvious internal control validation. 5 Gating WBCs by light scattering properties is suboptimal to select pure populations. The RBC assay should be performed with specific gating using an anti-glycophorin A (CD235a) antibody. This is necessary to avoid the inclusion of debris, which could be confused with deficient RBCs.
With its higher density, CD59 is best suited to discriminate partial Medische Laboratoriumdiagnostiek) (n = 6), UK-NEQAS (United Kingdom National External Quality Assessment Service) (n = 9) and HPN-AFC (PNH-Association Française de Cytométrie) (n = 8).
| Screening of high-risk groups
The presence of a PNH clone may result in a wide range of clinical signs and symptoms, including haemolysis, bone marrow dysfunction and thrombosis. 16 However, only a minority of patients with these symptoms is likely to have a PNH clone and requires testing for PNH. 5, 6 Therefore, physicians must focus on recognising specific high-risk groups for PNH testing. Table 1 gives an overview of patients for whom PNH testing is highly recommended.
The first high-risk group includes patients with haemolysis without an obvious cause. 5, 6 Any case of Coombs negative haemolytic anaemia without RBC abnormalities on a blood smear, as well as patients with unexplained haemoglobinuria, either microscopic or gross, should be tested for PNH (recommendation level C). As chronic intravascular haemolysis can lead to renal disease, unexplained haemolysis in addition to signs of renal failure is an indication for PNH testing as well. [16] [17] [18] (recommendation level C).
However, evidence of haemolysis is not always present in subclinical PNH setting. 
| MAIN CLINI C AL MANIFE S TATI ON S OF PNH
| Haemolysis
Complement-mediated haemolysis is the central mechanism underlying the morbidity and mortality associated with PNH 2 and is TA B L E 1 High-risk groups that should be screened for PNH associated with symptoms such as dyspnoea, chest and abdominal pain. A retrospective analysis of the South Korean National PNH Registry showed that PNH patients with elevated LDH levels (≥1.5
times the upper limit of normal [ULN]) had a significantly higher risk for thromboembolic events (TE) 22 and a 5-fold greater risk of mortality as compared to patients with LDH <1.5 × ULN. 
| Thrombosis
Thrombotic events occur in 40% of PNH patients. 19, 24 In these patients, the thrombosis occurs in the veins in 85% of the cases. 25 Thrombosis in PNH frequently involves multiple sites and can affect unusual sites, such as hepatic veins (Budd-Chiari syndrome), cavernous sinus, central nervous system veins, mesenteric veins or dermal veins. 20 When entering the International Registry, 13.6% of the Belgian PNH patients had a history of a TE ( Table 2) . Of these TEs, 75%
were of venous origin and arterial thrombosis occurred in 25% of the cases. To compare, 15.5% of the PNH patients at baseline in the International Registry had a history of thrombosis. 16 Treating thrombosis represents a major challenge in PNH, since thrombosis progression and recurrence still occurs despite anti-thrombotic therapy. 26, 27 The exact pathophysiology of the hypercoagulable state in PNH is unknown, but current data suggests that it has a multifactorial cause. 19, 28 Providing primary prophylactic anticoagulation in PNH patients is not an easy decision and there is no randomised trial evaluating the risks versus benefits of such an approach. For example, some data suggest that warfarin reduces the thrombotic risk in PNH patients but this strategy is at the cost of a significant, and sometimes fatal, bleeding risk. 25, 29 However, about 50% of TE occur during anticoagulation therapy, and these are often secondary TEs, such as BuddChiari syndrome relapse. 30 Eculizumab has shown to be effective in reducing the incidence rate of TEs. 30 Based on current knowledge, the Panel recommends the prophylactic use of eculizumab in PNH patients during pregnancy and for at least 3 months postpartum (recommendation level B) (see also: management of PNH and pregnancy).
In case of serious PNH-related acute thrombosis, eculizumab should be started without delay, together with therapeutic anticoagulation.
Additionally, in patients suffering from acute hepatic vein thrombosis, mesenteric vein thrombosis or a life-threatening pulmonary embolism, thrombolytic therapy should be considered.
24,25,31
Moreover, once a TE occurred, anticoagulation alone as secondary prophylaxis is not sufficient and complement inhibition should be ideally added (recommendation level A-B). Unfortunately, the current reimbursement criteria in Belgium do not always permit the use of eculizumab for these indications. The Panel's opinion is that this should be changed for the benefit of patients.
| Few clinical risk factors for thrombosis have been identified in PNH patients
A previous history of thrombosis is the main prognostic factor for overall survival in PNH patients, even when treated with complement inhibition. 32 In addition, age above 55 years, pregnancy and the post-partum period are associated with an increased thrombosis risk. Also, transfusion need is another independent risk factor. 26, 33 Finally, some reports have suspected ethnic differences to contribute to thrombotic risk, although this remains controversial.
24,34
| Biological markers of thrombotic risk have been identified for PNH
The presence of a large WBC PNH clone has been associated with an increased risk of thrombosis. 16, 24, 29 However, Lee et al 22 failed
to demonstrate any association between clone size and the risk of thromboembolism. As such, the thrombotic risk should not only be evaluated in terms of clone size.
Grünewald et al 35 observed an increased concentration of D-dimers in PNH patients vs control patients. Various studies demonstrated that D-dimer levels were elevated before eculizumab therapy and decreased significantly during treatment. [36] [37] [38] This suggests that D-dimers may be used as a haemostatic activation marker in PNH;
however, these are not specific. The challenge is to further identify thrombotic risk factors and markers for PNH. On the basis of these findings, clinicians could define subgroups of PNH patients that benefit from prophylactic treatment.
| Reduction of thrombotic risk factors for PNH
It is important to reduce cardiovascular (CV) disease risk in PNH patients. In the presence of CV risk factors, aspirin is justified as primary
prophylaxis. In case of thrombocytopenia, the advantages and disadvantages of aspirin use should be discussed on an individual basis.
In young women, oral oestro-progestative contraception should be avoided, as well as the use of a vaginal ring (recommendation level C). Progestative contraception or an intra-uterine device is considered to be feasible alternatives (recommendation level C).
In case of immobilisation, prophylactic treatment with LMWH is advised, as well as wearing compression stockings.
| Cytopenia
AA and MDS are frequently associated with subclinical PNH clones, in 50%-60% and 15%-20% of the cases, respectively. In most of the patients with a combined PNH-bone marrow failure syndrome, the size of the PNH clone is small. 40 Cytopenia is the main clinical feature in these patients and haemolysis is not predominant. For that reason, the underlying BMF is primarily treated (see:
PNH/SAA patients have a significantly lower median granulocyte PNH clone size, lower LDH values and equal TEs compared with classic PNH patients. 40 The survival of PNH/SAA patients is worse compared to classic PNH, mainly because of infections and critical bleeding events. 40 Of the Belgian PNH patients included in the International Registry, 33.9% were related to AA and 6.8% to MDS (Table 2 ).
| Pulmonary hypertension
An analysis of the first 1.610 PNH patients of the International PNH registry showed that 64% of the patients report dyspnoea. 16 Shortness of breath is multifactorial in PNH: it is related to anaemia and fatigue in most cases, however pulmonary hypertension (PHT) also contributes to this symptom. PHT has been reported in 1.9%
of the Belgian PNH patients (cfr Table 2 ) and dyspnoea in 36% (cfr Table 3 ).
Cell-free plasma haemoglobin depletes nitric oxide (NO) levels leading to smooth muscle dystonia and increased vasomotor tone. This process ultimately causes PHT. Elevated levels of NT-proBNP have been detected in PNH patients and reflect an increased pulmonary arterial resistance. 41 Doppler-echocardiography showed elevated systemic-pulmonary arterial pressure in 36% of the PNH patients. 42 In PNH patients, subclinical small pulmonary emboli (PE) also contribute to PHT. Cardiac MRI shows subclinical PE in 60% of the cases.
42
Moreover, Eculizumab treatment results in reduced pulmonary vascular resistance due to the inhibition of intravascular haemolysis. 41 Importantly, pulmonary hypertension should be managed in a multidisciplinary team, involving pneumologists to consider whether more specific treatments, such as intravenous prostacyclins or endothelin receptor agonists, are indicated. 
| Renal dysfunction
Chronic renal insufficiency (CRI) in PNH patients is caused by haemosiderin deposition in the proximal tubules of the renal cortex. 44 This is the result of repeated micro-infarctions due to microvascular thrombosis or reduced kidney perfusion caused by low NO levels. 45 Moreover, acute renal insufficiency can occur during a severe PNHcrisis with haemoglobinuria.
The international PNH registry reports a history of impaired renal function at baseline in 14% of the patients. 16 In the Belgian registry this is 9.3% (see Table 2 ). Renal insufficiency occurs in 44% of the classic PNH patients, in 10% of the patients with PNH in the setting of another bone marrow disorder (PNH/SABMD) and in 14% of subclinical PNH patients. 46 Eighteen per cent of these patients had severe renal insufficiency and required dialysis. 47 Of note, impaired renal function independently predicts mortality in PNH patients. 23 Eculizumab improves kidney function over time by reducing intravascular haemolysis and cell-free plasma haemoglobin. In this respect, Hillmen et al 47 showed that 44% of PNH patients with CRI experienced improvements of their renal function following 3 years of eculizumab treatment, while 48% had a stable kidney function.
However, no distinction was made between increased filtration because of reduced vasomotor spasm of renal arterioles and a real improvement of renal function.
| Erectile dysfunction
Erectile dysfunction (ED) frequently occurs in classic PNH patients.
ED has been reported in 53% of the male classic PNH patients and in 6% of patients with PNH/SABMD. In contrast, ED does not occur in subclinical PNH patients.
47
Specific ED-treatment can be initiated without risk. Since NO depletion is the underlying pathophysiologic mechanism of ED, additional treatment is often not required when the PNH patient is on eculizumab.
12.5% of the male Belgian patients in the PNH registry reported erectile dysfunction (Table 3 ), compared to 38% in the International Registry. 
| Abdominal pain
Abdominal pain is present in approximately one third of PNH patients at diagnosis and it is associated with a higher risk of TE. 22, 26 Recently, evidence supports the differences in mesenteric flow and in small bowel wall perfusion in PNH patients with and without abdominal pain. 48 can also be the cause of severe abdominal discomfort.
In the subanalysis of the Belgian PNH patients included in the International Registry, 32% of patients reported abdominal pain at baseline (Table 3 ).
| Thoracic pain due to oesophageal spasms
Oesophageal spasms rarely occur in patients with PNH/SABMD or in subclinical PNH patients. However, chest pain due to oesophageal spasms does occur in 51% of classic PNH patients. 46 This symptom is mainly caused by NO depletion and the successive effect on the smooth muscles of the oesophagus.
| Neurological complications
Thrombosis is the main cause of neurological complications in PNH patients. In fact, 13% of TE in PNH are arterial cerebrovascular accidents or transient ischaemic attacks. 49 Cerebral venous thrombosis (CVT) is reported in 2%-8% of PNH patients. 50 The prognosis of CVT is good if complement inhibition is started promptly. Recently, posterior reversible encephalopathy syndrome (PRES) has been described in a PNH patient on treatment with methylprednisolone. 51 
| Fatigue
Overall, 80% of PNH patients included in the International Registry reported fatigue. 16 In the Belgian subanalysis, 82% of patients mentioned fatigue to their physician ( Table 3 ). The consequences of fatigue in PNH are often underestimated; therefore, symptom scores should be used in the follow-up of PNH patients to avoid underreporting.
| PNH TRE ATMENT
Terminal complement inhibition and allogeneic haematopoietic stem cell transplantation (HSCT) are the only effective and approved therapies for patients with PNH. Not all patients require treatment and in cases, the PNH clone may disappear spontaneously. 52 However, if treatment is needed, the type of therapy depends on the clinical form of the disease: subclinical PNH, PNH/SABMD or classic PNH.
| Subclinical PNH
In subclinical PNH, patients are asymptomatic and do not need any treatment. 53 However, it is necessary to closely monitor these patients because an expansion of the PNH clone or the cells with a PNH phenotype may occur and patients can develop classic PNH (see: eculizumab-treated PNH patients).
| PNH in the setting of another bone marrow disorder
As mentioned before, a PNH clone can be found in the context of AA or MDS. In these cases, the treatment is primarily based on the underlying BMF (recommendation level C). This may require immunosuppressive therapy or a HSCT. IST for non-severe AA consists of treatment with cyclosporine A (CsA). Severe or very severe AA, not considered for HSCT (see below), are treated with ATG in combination with CsA, with responses up to 60%-70%. Relapses are described in one third of the responders. 54 In most cases, the size of the PNH clone does not change during IST. Rarely, IST in patients with AA that have a large PNH clone, may result in a clonal expansion of the PNH clone with worsening of haemolysis or thrombosis. 55 In that case, the patient should be treated as a patient with classic PNH. Although most published data suggest myeloablative conditioning regimens, nonmyeloablative conditioning could be sufficient to eradicate the PNH clone and may allow to maintain fertility.
2,56
Nevertheless, prospective evidence to guide our choice of conditioning and stem cell source is lacking.
56
Retrospective EBMT data suggest that transplant outcome is considerably worse for PNH patients with previous events of significant thrombosis. 56 In a remarkable study, a model was built to predict survival and health care costs after eculizumab vs allotransplant therapy. 59 The model relied on assumptions for mortality associated risk with each treatment. According to this model, allotransplant was associated with lower costs and an improved survival for patients <35 years old. 59 These data do not replace the necessity of prospective trials, but provide the incentive to further study allotransplant in PNH, especially for young patients with HLA matched sibling donors.
| Eculizumab
Management of classic PNH has been revolutionised by the development of eculizumab. This humanised monoclonal antibody blocks the activation of terminal complement C5 and prevents the formation of C5a and C5b-9. An induction dose of 600 mg is given IV every 7 days for four doses, followed by 900 mg 7 days later and maintenance therapy of 900 mg every 14 days (recommendation level A). Up to 50% of patients experienced headaches after the first dose of eculizumab, caused by the acute increase of NO levels. 47 The main risk of terminal complement blockade by eculizumab is life-threatening Neisserial infections (0.42 infections per 100 patient-years). 47 Therefore, it is mandatory that all patients treated with eculizumab are vaccinated against Neisseria meningitidis, at least 2 weeks before starting eculizumab (recommendation level C). In severe PNH, where eculizumab treatment cannot be postponed, 2 weeks of prophylactic therapy with ciprofloxacin is recommended after vaccination. Some investigators propose prophylactic treatment with penicillin in younger patients, but this has not been formally studied. 2 The efficacy and safety of eculizumab have been demonstrated in 2 phase III trials and in an extension study. The TRIUMPH study
showed that eculizumab was able to reduce haemolysis and transfusion requirements in transfusion-dependent PNH patients. 60 In a second, open-label, phase III study (SHEPHERD), the long-term safety and efficacy of eculizumab were assessed. In total, 97 patients with a median age of 41 years were enrolled in this trial and were followed for 52 weeks. Eighty-nine of the 97 patients demonstrated a fast response and maintained a complete inhibition of haemolysis. 61 Moreover, long-term safety and efficacy of eculizumab has been shown over 66 months of treatment. 47 The drug is highly effective in stopping intravascular haemolysis, eliminating or decreasing the need for red cell transfusions, improving QoL and reducing the risk of thrombosis. 49 However, eculizumab is expensive and must be administered indefinitely to maintain a response. Nevertheless, it has definitively changed the management of this disease. 
| Extravascular haemolysis
As eculizumab blocks the complement pathway at the level of C5, the upfront steps in the complement cascade (including activation, deposition and proteolytic cleavage of C3 to C3b and further split products) are not affected by eculizumab. As a result, PNH patients on eculizumab treatment may continue to experience a variable degree of extravascular haemolysis. 63 This explains why over 50%
of PNH patients treated with eculizumab exhibit a positive direct antiglobulin test (C3 positive but IgG negative) in conjunction with anaemia and an elevated reticulocyte count. 64 For that reason, some PNH patients on eculizumab could remain transfusion-dependent.
| Breakthrough haemolysis
The recommended eculizumab doses and intervals have been designed to maintain a permanent complement blockade. However, individual patients may need different dosages and various events (eg, infection, surgery, pregnancy) may influence the complement activity and eculizumab concentrations. When 2 consecutive periods of breakthrough haemolysis occur, dose adjustments should be considered 63 (recommendation level C).
Eculizumab and the use of anticoagulation
When oral anticoagulants (OAC) are given as primary prophylaxis prior to the start of eculizumab, some physicians stop OAC once eculizumab treatment started. Indeed, OAC could be stopped when the patient is administered a maintenance dose of eculizumab for some weeks in the absence of signs of haemolysis, but evidence is not sufficient to consider this strategy as a Panel recommendation.
In case of secondary prophylaxis, the risk/benefits of continuous anticoagulation should be evaluated on an individual basis.
19,65
Use of non-vitamin K antagonist oral anticoagulants (NOAC) in acute thrombosis has not been studied in PNH patients.
Special situations
Pregnancy A retrospective analysis suggests that 25% of female PNH patients are diagnosed during pregnancy. 66 This could be the consequence of the increased frequency of standard routine blood tests as part of antenatal care. Moreover, it might also be related to the increased complement activity during pregnancy. Reports of pregnant women with PNH in the pre-eculizumab era mention maternal and foetal mortality rates of 8%-12% and 4%-7%, respectively. 67, 68 Eculizumab proved to be beneficial for PNH patients during pregnancy, as evidenced by a high rate of foetal survival and a low rate of maternal complications. 69 Eculizumab could be detected in cord blood but was not detectable in breast-milk samples. 69 The use of eculizumab during pregnancy is still off-label. However, based on the published data, the Panel recommends prophylactic use of eculizumab until 3 months post-partum in pregnant women with PNH (recommendation level B). An increase in dose administration of eculizumab to avoid breakthrough haemolysis is almost in every case indicated during pregnancy. Depending on the personal and familial history, the use of LMWH can be considered during pregnancy until 6 weeks post-partum (recommendation level C).
Management of PNH patients undergoing surgery When a patient is already on eculizumab, surgery should be performed within 7 days after the last eculizumab infusion. In an emergency setting, an additional infusion is required if the last administration was more than 7 days ago (recommendation level C).
PNH patients with infections
In case of an infection, adequate treatment needs to be initiated and eculizumab treatment should be continued (recommendation level C). Increased complement activation during the infection can result in breakthrough haemolysis, which could require dosage adjustments of eculizumab.
Travelling patients It is possible to extend the interval between two infusions of eculizumab to a maximum of 15 or 16 days without a risk for breakthrough haemolysis. 70 In case of exceeding this interval in case of travelling, eculizumab administration should be organised in the country of destination.
Discontinuation of eculizumab On rare occasions, eculizumab treatment can be discontinued. As such, before initiating eculizumab therapy, patients should be well informed that the treatment will be continued permanently.
Stopping eculizumab therapy is only considered (recommendations level C):
• When the PNH clone size decreases gradually over time and gets consistently below 10%.
• When there is a C5 polymorphism resulting in resistance to eculizumab treatment.
• In case of an allogeneic stem cell transplantation.
| FOLLOW-UP OF PNH PATIENTS
| Untreated PNH patients
It is recommended that patients with a PNH clone size of more than 0.01% should be monitored regularly depending on the clinical manifestations and clone size. For instance, in the absence of clinical manifestations, a patient with a clone size of <1% should be tested every year. In contrast, patients with a clone size of more than 1%, testing should be performed at least once every 6 months (recommendation level C). As indicated before, spontaneous disappearance of a PNH clone is rarely seen. 52 However, an increase in the PNH clone might indicate that the disease is becoming more active. Moreover, in case of deterioration of clinical symptoms, TE or increased haemolysis, immediate testing is recommended. 5, 6, 71, 72 In these cases, haemolysis parameters, iron status and renal function should be measured frequently. Additionally, an echocardiography and NT-proBNP levels measurement should be repeated every year.
As PNH is a BMF, bone marrow sampling with cytogenetics should be performed every 2 years.
| Eculizumab-treated PNH patients
PNH patients receiving eculizumab therapy should be monitored with a complete blood count, haemolysis parameters and biochemical profile during the first 4 weeks of treatment.
Eventually, a monthly evaluation is warranted (recommendation 
| Patient education and quality of life
The symptoms of PNH have a major adverse impact on the patient's QoL. It is important to monitor the burden of these symptoms, even in patients with a small clone size. PNH patients should be managed in a multidisciplinary environment with a rapid and easy access to evaluation by different specialists (cardiologists, pneumologists, nephrologists, etc). In addition, PNH patients and their relatives should receive sufficient education about the disease and the possible complications.
| PNH REG IS TRY AND DATA OF B ELG IAN PNH PATIENTS
| Importance of PNH patient registries and biobanking
The study of rare diseases, such as PNH, requires access to data on a large number of patients to perform appropriate statistics.
This can be achieved by implementing strict regulations for data collection.
A first important step to join efforts in PNH research is establishing a biobanking network that includes the collection and storing of biological material (blood, bone marrow and other tissues). Biobanks should be able to exchange information in a transparent way and their establishment should be encouraged.
A second approach is to improve the availability of patient regis-
tries. An international PNH registry is operational since 2008, allowing the collection of patient data from numerous countries, including
Belgium. This registry shares data, both on a national and international level, and contributes to a better knowledge of the pathophysiology and epidemiology of PNH. As such, it is possible to define risk factors and adapt the treatment in specific high-risk groups.
However, in our opinion the International PNH registry could still be improved in generating more data on infection rates, causes of death and transfusion rates and in providing separate data for patients who receive eculizumab treatment or not.
| The PNH registry in Belgium
Belgian patients have been included in the international registry since 2009. On a national level, every haematologist managing PNH patients is able to participate in the registry and every PNH patient, regardless of clone size or treatment, is eligible to enrol. The enrolment of Belgian patients is depicted in Figure 1 .
Strikingly, the number of patients ever treated with eculizumab is higher than the number of patients never treated with eculizumab in the Belgian cohort. This is not the case in the international PNH registry. Most likely, a group of untreated Belgian PNH patients is still not included in the registry and should be reached in the future. angiogenesis, haemostasis and thrombosis. 73, 74 Exposing phosphatidylserine on their surface (a support for the assembly of procoagulant enzyme complexes) and containing tissue factor, their procoagulant properties are described in various pathological states. 74, 75 In addition to this, EVs convey fibrinolytic properties and could play a regulatory role in balancing coagulation and fibrinolysis. 76 In PNH, the complement activation at the cell surface of GPIdeficient cells results in the release of procoagulant EVs. Indeed, increased levels of circulating EVs, mostly of platelet origin, are described in PNH. However, no correlation was found between the number of EVs and the clone size. 77 
| Development of novel complement inhibitors
Several novel complement inhibitors are currently in development. A C5 complement inhibitor with a longer half-life as eculizumab, ALXN1210, is given intravenously every 8 weeks. 81 In addition to this, recently presented data of a phase I trial with a novel C5 inhibitor, RA101495, are encouraging given the fact that this molecule can be administered subcutaneously. 82, 83 A novel RNA interference (RNAi) therapeutic targeting C5, ALN-CC5, was shown to be well tolerated and safe when given subcutaneous on a weekly base. 84 A PNH patient, resistant to eculizumab due to C5 polymorphisms, was successfully treated with a novel small protein complement inhibitor, coversin. This molecule was given subcutaneously but seemed to have a short half-life. 85 Finally, an oral complement D inhibitor, ACH-4471, is also in development. 86 In summary, these early clinical data look promising and offer new therapeutic perspectives for PNH patients.
| CON CLUS IONS
This paper reviewed the current standards for diagnosis of PNH, the indications for therapy and the different therapeutic options for PNH patients, with a focus on identifying high-risk patients. Rapidly starting therapy in these patients is essential. Eculizumab reduces haemolysis and thrombosis in PNH patients in a safe and effective way.
The first trials with eculizumab focused on transfusion-dependent PNH patients. However, nowadays the effects of eculizumab on other clinical manifestations have also been established. Novel complement inhibitors are in development and the first data with these agents are encouraging.
Another challenge in PNH is the identification of novel markers to assess the thrombosis risk. This would allow a better risk-based prophylactic anti-thrombotic management. Finally, because of the rarity of the disease, PNH patients should be included in prospective PNH registry. This registry will offer new insights on the natural course of the disease and the impact of treatment of PNH. Moreover, the PNH registry allows for a comparison between local and global data and facilitates the exchange of information. Systematic biobanking of samples of PNH patients will also add to a better understanding of the disease and should be encouraged.
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